A Fresh Chapter is a non-profit organization that facilitates life-changing volunteer and leadership experiences to empower people impacted by cancer. AFC programs blend volunteerism and meaningful travel to connect cancer patients and caregivers around the globe, and focus on healing the often over-looked emotional scars left by cancer. AFC’s perspective-shifting journeys to places like India, Peru and Kenya help participants reframe adversity and discover a new perspective and purpose in their lives.
Here is a list of conditions this partner raises awareness and advocacy for:
The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have
HPV or human papillomavirus is the most common sexually transmitted disease in the US. It is so common that most sexually active people will
One huge goal throughout the medical world is to find effective and well-tolerated treatments for patients with cancer. According to News Medical, researchers recently
As reported by Oncology Nursing News, gunagratinib (ICP-192) was recently granted Orphan Drug designation by the FDA. Altogether, this treatment is being evaluated as
According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical’s ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+)
As reported in Fierce Pharma; BridgeBio has earned FDA approval for their new targeted cancer treatment, Truseltiq. The approval is the biotech company’s first ever
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
